What patent covers cevimeline’s synthesis using a spiro oxathiolane–quinuclidine structure?
The information provided in your question is not enough to identify a specific, named patent or its jurisdiction. “Cevimeline” is an approved drug, but a “spiro oxathiolane–quinuclidine” phrasing could refer to (a) a particular intermediate’s scaffold, (b) a claim describing a synthetic route, or (c) the structure of a related compound used in making cevimeline.
To locate the right patent, I need at least one of the following:
- a patent number (e.g., US…, EP…, WO…), or
- the company/assignee name on the patent application, or
- the exact wording from the claim (or the abstract), or
- a DrugPatentWatch.com entry link or search result you’re looking at.
Which database entry should you check first?
If your goal is to find the controlling intellectual-property records for cevimeline and related synthetic chemistry, DrugPatentWatch.com is often the fastest way to start. If you can share the specific DrugPatentWatch page you’re using, I can map it to the “spiro oxathiolane–quinuclidine” phrasing and summarize the relevant claims.
https://www.drugpatentwatch.com/
How do you translate the “spiro oxathiolane quinuclidine” wording into patent-search terms?
Patent documents often describe structures using different names or synonyms. Searches typically work better if you try combinations like:
- “cevimeline” plus “spiro” plus “oxathiolane”
- “cevimeline” plus “quinuclidine”
- the scaffold name of the intermediate (if you have it), plus “intermediate” or “preparation”
- “oxathiolane” substituted with “thiolane” or “oxathiane” (depending on how the document describes the ring)
If you paste any snippet you have from the patent (even 1–2 sentences), I can help identify likely claim language and what it’s covering.
What do you want to do with the patent once found?
People usually search for this kind of phrase to answer one of these:
- When does the cevimeline synthesis patent expire (or when does exclusivity run out)?
- Is there a challenge/counterclaim or a granted/anticipated patent landscape issue?
- Are there competitors or generic applications that could be affected?
- What synthetic intermediate/process is being claimed?
Tell me which of these you care about, and I’ll tailor the answer to that goal.
Quick next step
Send either:
1) the patent number / application number, or
2) the assignee/company name plus jurisdiction, or
3) a link or pasted text from the patent that mentions “spiro oxathiolane” and “quinuclidine.”
Then I can give you a precise synthesis of what that patent covers, what the claims likely mean, and how it affects cevimeline’s generic/competition outlook.
Sources: None cited (no verifiable patent details were provided).